scispace - formally typeset
R

Runyu Yang

Researcher at Nanjing Tech University

Publications -  7
Citations -  151

Runyu Yang is an academic researcher from Nanjing Tech University. The author has contributed to research in topics: Limonin & Internal medicine. The author has an hindex of 4, co-authored 5 publications receiving 48 citations.

Papers
More filters
Journal ArticleDOI

Limonin ameliorates acetaminophen-induced hepatotoxicity by activating Nrf2 antioxidative pathway and inhibiting NF-κB inflammatory response via upregulating Sirt1.

TL;DR: Limonin mitigated APAP-induced hepatotoxicity by activating Nrf2 antioxidative pathway and inhibiting NF-κB inflammatory response via upregulating Sirt1, and demonstrated that limonin had therapeutic promise in AP AP-induced liver injury.
Journal ArticleDOI

Glaucocalyxin A reverses EMT and TGF-β1-induced EMT by inhibiting TGF-β1/Smad2/3 signaling pathway in osteosarcoma

TL;DR: It is demonstrated that Glaucocalyxin A inhibited EMT and TGF-β1-induced EMT by inhibiting TGF -β1/Smad2/3 signaling pathway in osteosarcoma.
Journal ArticleDOI

Limonin Attenuates LPS-Induced Hepatotoxicity by Inhibiting Pyroptosis via NLRP3/Gasdermin D Signaling Pathway.

TL;DR: In this paper, the authors investigated the protection of limonin, an antioxidant compound from citrus fruit, against LPS-induced liver toxicity and elucidate the potential mechanisms, and they found that limonins elevated cell viability and reduced LDH release in LPS treated HepG2 cells.
Journal ArticleDOI

Limonin ameliorates dextran sulfate sodium-induced chronic colitis in mice by inhibiting PERK-ATF4-CHOP pathway of ER stress and NF-κB signaling

TL;DR: Limonin relieved the risk and severity of DSS-induced chronic colitis in mice through various aspects including increasing body weight and colon length, decreasing the mortality rate, inhibiting MPO activity and improving colon pathology, and provides the possibility for limonin as an effective drug for chroniccolitis of IBD in the future.
Journal ArticleDOI

Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction

TL;DR: In this article , the role of RIPK2 in prognosis and immunotherapy response is yet to be elucidated in human pan-cancer by investigating the expression, gene alteration landscape and prognostic value of RIPk2 in 33 cancers through various databases including Ualcan, cBioportal and Gene Expression Profiling Interactive Analysis 2.